Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Z drugs

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    138 result(s) found for: Z drugs. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2017-000994-35 Sponsor Protocol Number: 06032017 Start Date*: 2018-08-02
    Sponsor Name:Hospital General Universitario de Alicante
    Full Title: Study of tolerability of iron liposome compared to ferrous sulphate in pregnant women with iron deficiency anemia.
    Medical condition: Iron deficiency anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002042 Anaemia deficiencies HLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000735-14 Sponsor Protocol Number: L-A/2017/COM/01 Start Date*: 2018-01-19
    Sponsor Name:Lek-Am Sp. z o.o.
    Full Title: The efficacy and safety of new formulation of combination of fluticasone propionate / salmeterol (125μg / 25μg) in MDI HFA inhaler compared with the reference drug at a dose of 500μg / 50μg in DPI...
    Medical condition: Asthma is a common, chronic respiratory disease affecting 1–18% of the population in different countries. Asthma is characterized by variable symptoms of wheeze, shortness of breath, chest tightnes...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001552-19 Sponsor Protocol Number: TOPMATEPY4067 Start Date*: 2014-12-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects ...
    Medical condition: New-onset or recent-onset epilepsy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) HU (Completed) BE (Completed) DE (Completed) GB (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000323-43 Sponsor Protocol Number: D6020C00001 Start Date*: 2017-10-31
    Sponsor Name:MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC
    Full Title: A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malign...
    Medical condition: clear-cell renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000072939 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000037-51 Sponsor Protocol Number: CA204-185 Start Date*: 2020-06-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) BE (Completed) ES (Ongoing) PL (Completed) HU (Completed) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004827-29 Sponsor Protocol Number: VX14-661-110 Start Date*: 2015-09-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, ...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) AT (Completed) FR (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000543-16 Sponsor Protocol Number: VX14-809-109 Start Date*: 2015-06-19
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fib...
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) DK (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001462-81 Sponsor Protocol Number: FARM7KP2PX Start Date*: 2008-10-27
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations
    Medical condition: Marfan Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026829 Marfan's syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000577-13 Sponsor Protocol Number: kajakbe191086 Start Date*: 2015-09-09
    Sponsor Name:Oslo University Hospital
    Full Title: Therapeutic effects of BNP in uncontrolled hypertensive patients 1
    Medical condition: Uncontrolled hypertension (UHT, i.e. blood pressure ≥ 150/90, or ≥ 150/85 mm Hg in diabetic patients) despite treatment with at least two different classes of antihypertensive medications.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000641-44 Sponsor Protocol Number: TailorDose-II Start Date*: 2017-04-28
    Sponsor Name:Karolinska intitutet
    Full Title: TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer
    Medical condition: Newly diagnosed pre- or post-operative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-005142-12 Sponsor Protocol Number: TMC207-C203 Start Date*: 2005-06-25
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of...
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001503-26 Sponsor Protocol Number: FER-CARS-03 Start Date*: 2008-10-17
    Sponsor Name:Vifor Pharma - Vifor (International) AG
    Full Title: EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac function in patients with iron deficiencY and chronic Heart Failure (EFFICACY-HF)
    Medical condition: Ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008908 Chronic heart failure LLT
    9.1 10002062 Anaemia iron deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000469-62 Sponsor Protocol Number: 2017-000469-62 Start Date*: 2017-07-24
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients
    Medical condition: HIV-1 infected solid organ transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10068341 HIV-1 infection LLT
    20.0 10022891 - Investigations 10057925 Transplant evaluation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001078-41 Sponsor Protocol Number: VX13-809-011 Start Date*: 2017-03-27
    Sponsor Name: Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozy...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005052-37 Sponsor Protocol Number: BRAVO Start Date*: 2021-04-01
    Sponsor Name:Institute of Mother and Child
    Full Title: Optymalizacja czasu leczenia i dawkowania wemurafenibu u małoletnich pacjentów z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych z obecnością mutacji w genie BRAF.
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016728-29 Sponsor Protocol Number: P-Monofer-CKD-02 Start Date*: 2010-02-03
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Phase III, randomized, comparative, open-label study of intravenous Iron Isomaltoside 1000 (Monofer®) administered by infusions or repeated bolus injections in comparison with oral Iron Sulphate ...
    Medical condition: Non-dialysis dependent chronic kidney disease and with renal-related anaemia (NDD-CKD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    14.0 10005329 - Blood and lymphatic system disorders 10022974 Iron deficiency anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed) IE (Completed) DE (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016727-53 Sponsor Protocol Number: P-Monofer-CIA-01 Start Date*: 2010-04-12
    Sponsor Name:Pharmacosmos A/S
    Full Title: A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjec...
    Medical condition: non-myeloid malignancies associated with chemotherapy induced anaemia (CIA).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064014 Cancer anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) SE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011774-15 Sponsor Protocol Number: BASt01 Start Date*: 2009-07-15
    Sponsor Name:Federal Highway Research Institute / Bundesanstalt für Straßenwesen (BASt)
    Full Title: Effects of opioid analgesics on driving ability of pain patients [Untersuchung zur Fahrsicherheit von Schmerzpatienten]
    Medical condition: patients suffering from chronic non-cancer pain responsive to opioid analgesics under already existing long-term treatment
    Disease: Version SOC Term Classification Code Term Level
    11.0 10067033 LLT
    9.1 10013496 Disturbance in attention LLT
    9.1 10027375 Mental impairment (excl dementia and memory loss) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000333-13 Sponsor Protocol Number: APHP200046 Start Date*: Information not available in EudraCT
    Sponsor Name:APHP DRCI
    Full Title: Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts
    Medical condition: Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005383-22 Sponsor Protocol Number: Kognition Start Date*: 2022-07-27
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: Cognitive Function, Depression, Anxiety, and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia: Effects of Intravenous Iron (Ferric Derisomaltose)
    Medical condition: Iron deficiency in patients with chronic heart failure and mild cognitive impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 10:44:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA